Multitarget drugs: Focus on the NO-donor hybrid drugs

24Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

The article addresses the design of multitarget drugs, namely, compounds capable of interacting with more than one target simultaneously. These agents could be useful tools in the therapy of complex diseases such as cardiovascular and inflammatory diseases. An interesting case of multitarget compounds are nitric oxide (NO)-donor hybrids, structures which combine the physiological properties of NO with those of a lead drug. In particular, the authors discuss the symbiotic approach used to design NO-donor nonsteroidal anti-inflammatory drugs (NO-NSAIDs) and NO-donor antioxidants. The former could be useful agents in the treatment of anti-inflammatory diseases being devoid of gastro- and cardio-toxicity, the latter could be a valid approach to the treatment of many cardiovascular diseases. © 2008 IUPAC.

Cite

CITATION STYLE

APA

Gasco, A., Boschi, D., Chegaev, K., Cena, C., Di Stilo, A., Fruttero, R., … Tosco, P. (2008). Multitarget drugs: Focus on the NO-donor hybrid drugs. In Pure and Applied Chemistry (Vol. 80, pp. 1693–1701). https://doi.org/10.1351/pac200880081693

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free